Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654674 | PMC |
| http://dx.doi.org/10.1161/CIRCHEARTFAILURE.115.002492 | DOI Listing |
Publication Analysis
Top Keywords
letter teerlink
4
teerlink article
4
article "myosin
4
"myosin activator
4
activator omecamtiv
4
omecamtiv mecarbil
4
mecarbil increases
4
increases myocardial
4
myocardial oxygen
4
oxygen consumption
4
Similar Publications
Omecamtiv Mecarbil in Systolic Heart Failure. Reply.
N Engl J Med
May 2021
University of Glasgow, Glasgow, United Kingdom.
The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF).
Eur J Heart Fail
June 2021
Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure: The COSMIC-HF Trial.
Circ Heart Fail
December 2020
Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (T.B.-S., M.M., B.C., J.L., S.D.S.).
A novel ribosomal protein S20 variant in a family with unexplained colorectal cancer and polyposis.
Clin Genet
June 2020
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!